United StatesThe article claims that under President Trump's administration, prescription drug prices have seen significant decreases, dropping from $1,000 to $149. It attributes these price reductions to policies implemented during his presidency. The piece emphasizes the need for Congress to regulate pharmacy benefit managers (PBMs), which are described as intermediaries in the pharmaceutical supply chain, to ensure that the cost savings are sustained over time.
Bias read (Conservative): The article frames the reduction in drug prices as a direct result of Trump's policies, implying a positive outcome from his administration. It calls for congressional action to address PBMs, suggesting a partisan angle by focusing on regulatory changes that align with conservative economic policies
%2Ffile%2Fdailymaverick%2Fwp-content%2Fuploads%2F2024%2F11%2FOpinion-Tusenius-TrumpTW.jpg&w=3840&q=75&output=webp&we)
